Safety and efficacy of eltrombopag in patients with post‐ CAR T cytopenias
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14141 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von William Wesson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Cytopenia, Thrombocytopenia, Anemia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
While chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment outcomes of relapsed/refractory hematological malignancies, this therapy is associated with post‐treatment cytopenias, which can pose a challenge to its safe administration. This study describes the management of post‐CAR T cytopenias using the thrombopoietin mimetic eltrombopag.
Methods
This retrospective analysis included adult patients with lymphoma or myeloma who received CAR T‐cell therapy at two academic medical centers. Eltrombopag was initiated for patients who had persistent high‐grade leukopenia and/or thrombocytopenia beyond 21 days post‐CAR T infusion. Risk factors and outcomes were assessed and compared for patients who did or did not receive eltrombopag.
Results
Among the 185 patients analyzed, a majority (88%) experienced thrombocytopenia or leukopenia at day +30 post‐CAR T infusion. A total of 42 patients met the criteria for eltrombopag treatment and initiated therapy. Patients who received eltrombopag were more likely to have pre‐existing cytopenias at lymphodepletion, receive bridging therapy, experience an infection, or require intensive care. Recovery from cytopenias occurred within 180 days for a majority (94%) of patients.
Conclusions
The use of eltrombopag for post‐CAR T leukopenia and thrombocytopenia was considered safe without any significant toxicities. The use of eltrombopag for post‐CAR T cytopenias might be effective in a high‐risk patient population but requires further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA.
- Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.
ORCID-Profile: William Wesson
Zitieren
APA
Wesson, W., Ahmed, N., Rashid, A., Tabak, C., Logan, E., Marchena-Burgos, J., Nelson, M., Davis, J. A., McGann, M., Shune, L., Hoffmann, M., Abdallah, A. O., & Hashmi, H. (2024). Safety and efficacy of eltrombopag in patients with post‐ CAR T cytopenias. European Journal of Haematology. https://doi.org/10.1111/ejh.14141
Vancouver
Wesson W, Ahmed N, Rashid A, Tabak C, Logan E, Marchena-Burgos J, et al. Safety and efficacy of eltrombopag in patients with post‐ CAR T cytopenias. European Journal of Haematology. 2024. doi:10.1111/ejh.14141
BibTeX
@article{Wesson2024,
author = {Wesson, William and Ahmed, Nausheen and Rashid, Aliya and Tabak, Carine and Logan, Emerson and Marchena-Burgos, Jose and Nelson, Maggie and Davis, James A and McGann, Mary and Shune, Leyla and Hoffmann, Marc and Abdallah, Al-Ola and Hashmi, Hamza},
title = {Safety and efficacy of eltrombopag in patients with post‐ CAR T cytopenias},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14141}
}
EUVIMED